Ms Michele Park

KANDO id: 42205

Bio

Michele Park, PhD, serves as a Principal of Clarus Ventures. Dr. Park joined Clarus with five years of sell-side equity research experience covering the biotechnology sector. From 2002-2005, Dr. Park was a research analyst at Credit Suisse First Boston, where she covered biotechnology stocks as a member of the firm’s US biotechnology team. Before joining CSFB, Dr. Park was a biotechnology research analyst at US Bancorp Piper Jaffray. Dr. Park is a member of the Board of Directors for Sientra and Board observer for Achillion, and SFJ Pharmaceuticals, LP. Dr. Park received a PhD in Molecular Biology from Cornell University’s Graduate School of Biomedical Sciences, completing her PhD dissertation at Memorial Sloan-Kettering Cancer Center, and a BA in Molecular Biology from Princeton University.

Career


Clarus Ventures LLC

Life sciences venture capital firm
N/A (past)

Education